Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.88 - $9.94
Previous CloseN/A
Volume7.67K
Average Volume (3M)1.70M
Market Cap
$87.25M
Enterprise Value-$20.44M
Total Cash (Recent Filing)$74.65M
Total Debt (Recent Filing)$17.86M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 06, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding32,799,725
10 Day Avg. Volume4,350,348
30 Day Avg. Volume1,697,767
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-13.70
Enterprise Value/Gross Profit57.57
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$8.33Price Target Upside64.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPEPG's ability to break the ceiling with their highest dose is a clear positive, indicating potential for a competitive clinical profile.
Market PotentialAn increase in the probability of success to 35% and the target price to $12 reflects confidence in the positive data and financing updates.
Strategic DevelopmentThe transition of clinical sites to FREEDOM2-DM1, a Phase 2 multiple ascending dose study, accelerates the clinical timeline and potentially saves 3-6 months.
Bears Say
Potential RisksOne patient experienced a transient, reversible renal biomarker elevation, indicating that the program might not be out of the woods yet.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $0.88 and its highest was $9.94 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $87.25M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Aug 07, 2025. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.846 by $0.146.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.56.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 32,799,725 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.846. Following the earnings report the stock price went down -13.139%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
PepGen Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.33 (64.30% Upside)
$8.33 (64.30% Upside)
Blogger Sentiment
Bullish
PEPG Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 89.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 25.5%
Last 30 Days ▲ 129.1%
Last 30 Days ▲ 129.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.70%
12-Months-Change
Fundamentals
Return on Equity
-85.69%
Trailing 12-Months
Asset Growth
-47.16%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc. (PEPG) is a biotechnology company focused on developing transformative therapies for patients with neuromuscular and neurological diseases. Leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen aims to deliver innovative solutions that improve the delivery and efficacy of oligonucleotides. The company's core products are designed to address unmet medical needs through targeted treatments that can enhance the quality of life for patients suffering from debilitating conditions.
PEPG Stock 12 Month Forecast
Average Price Target
$8.33
▲(64.30% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Dyadic International
―
X4 Pharmaceuticals
―
Xilio Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
33.21% Insiders
4.69% Mutual Funds
50.26% Other Institutional Investors
9.03% Public Companies and
Individual Investors